6533b824fe1ef96bd1280b21
RESEARCH PRODUCT
Deciphering Multiple Sclerosis Progression
Virginia Meca-lallanaLeticia Berenguer-ruizJoan Carreres-poloSara Eichau-madueñoJaime Ferrer-lozanoLucía ForeroYolanda HiguerasYolanda HiguerasNieves Téllez LaraAngela Vidal-jordanaFrancisco Carlos Pérez-mirallesFrancisco Carlos Pérez-mirallessubject
Oncologymedicine.medical_specialty:Other subheadings::Other subheadings::/physiopathology [Other subheadings]:Otros calificadores::Otros calificadores::/fisiopatología [Otros calificadores]Esclerosi múltiple - Propensió:Genetic Phenomena::Genotype::Genetic Predisposition to Disease [PHENOMENA AND PROCESSES]ReviewDiseaseneurofilamentEsclerosi múltiple - Fisiologia patològicamultiple sclerosislcsh:RC346-429Sistema nerviós - Degeneració03 medical and health sciences0302 clinical medicineDegenerative diseaseInternal medicinemedicineIn patient030212 general & internal medicine:enfermedades del sistema nervioso::enfermedades neurodegenerativas [ENFERMEDADES]lcsh:Neurology. Diseases of the nervous system:fenómenos genéticos::genotipo::predisposición genética a la enfermedad [FENÓMENOS Y PROCESOS]Expanded Disability Status Scalebusiness.industryMultiple sclerosisNeurodegenerationDisease progressionneurodegeneration:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]medicine.diseaseClinical trialprogressive multiple sclerosisNeurology:Nervous System Diseases::Neurodegenerative Diseases [DISEASES]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Neurology (clinical)business030217 neurology & neurosurgeryMRIdescription
Esclerosi múltiple; Neurodegeneració Esclerosis múltiple; Neurodegeneración Multiple sclerosis; Nneurodegeneration Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological disability is one of the essential goals to be achieved in a patient with MS. However, the pathogenic mechanisms driving the progressive phase of the disease remain unknown. It was described that the pathophysiological mechanisms associated with disease progression are present from disease onset. In daily practice, there is a lack of clinical, radiological, or biological markers that favor an early detection of the disease's progression. Different definitions of disability progression were used in clinical trials. According to the most descriptive, progression was defined as a minimum increase in the Expanded Disability Status Scale (EDSS) of 1.5, 1.0, or 0.5 from a baseline level of 0, 1.0–5.0, and 5.5, respectively. Nevertheless, the EDSS is not the most sensitive scale to assess progression, and there is no consensus regarding any specific diagnostic criteria for disability progression. This review document discusses the current pathophysiological concepts associated with MS progression, the different measurement strategies, the biomarkers associated with disability progression, and the available pharmacologic therapeutic approaches.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-04-01 |